Education
About Us
Working with TipRanks
Follow Us
Wanbury Limited (IN:WANBURY)
:WANBURY
WANBURY Stock Chart & Stats
Day’s Range― - ―
52-Week Range₹155.00 - ₹330.00
Previous CloseN/A
Volume54.35K
Average Volume (3M)6.87K
Market Cap
₹8.97B
Enterprise Value₹11.07B
Total Cash (Recent Filing)₹150.63M
Total Debt (Recent Filing)₹1.77B
Price to Earnings (P/E)29.4
Beta2.13
Next Earnings
Aug 07, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jul 29, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)6.18
Shares Outstanding32,770,496
10 Day Avg. Volume5,035
30 Day Avg. Volume6,872
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)15.76
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Wanbury Limited News
PremiumCompany Announcements
Expert Chemicals Affirms No New Share Encumbrances for FY 2025
PremiumCompany Announcements
Wanbury Limited Strengthens Board with New Director Appointments
PremiumCompany Announcements
Wanbury Limited Appoints New Independent Directors to Strengthen Governance
PremiumCompany Announcements
Wanbury Limited Announces Financial Results and Capital Raising Initiatives
PremiumCompany Announcements
Wanbury Limited’s Strategic Financial Moves and Employee Incentives
PremiumCompany Announcements
Wanbury Limited Announces Debenture Issuance and ESOP GrantPremiumCompany Announcements
Wanbury Limited Announces Financial Results and Strategic Initiatives
PremiumCompany Announcements
Wanbury Limited Announces Key Financial and Strategic InitiativesWANBURY FAQ
What was Wanbury Limited’s price range in the past 12 months?
Wanbury Limited lowest stock price was ₹155.00 and its highest was ₹330.00 in the past 12 months.
What is Wanbury Limited’s market cap?
Wanbury Limited’s market cap is ₹8.97B.
When is Wanbury Limited’s upcoming earnings report date?
Wanbury Limited’s upcoming earnings report date is Aug 07, 2025 which is in 24 days.
How were Wanbury Limited’s earnings last quarter?
Wanbury Limited released its earnings results on May 15, 2025. The company reported ₹6.18 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.18.
Is Wanbury Limited overvalued?
According to Wall Street analysts Wanbury Limited’s price is currently Overvalued.
Does Wanbury Limited pay dividends?
Wanbury Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Wanbury Limited dividends here
What is Wanbury Limited’s EPS estimate?
Wanbury Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wanbury Limited have?
Wanbury Limited has 32,770,496 shares outstanding.
What happened to Wanbury Limited’s price movement after its last earnings report?
Wanbury Limited reported an EPS of ₹6.18 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.669%.
Which hedge fund is a major shareholder of Wanbury Limited?
Currently, no hedge funds are holding shares in IN:WANBURY
Company Description
Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Kilitch Drugs (India) Limited
―
Kopran Limited
―
Lincoln Pharmaceuticals Ltd
―
Sakar Healthcare Ltd
―
Themis Medicare Limited
―